Head and neck squamous cell carcinoma

Results 291 to 300 of about 198,685 (310)

Some of the next articles are maybe not open access.

Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis

Head and Neck, 2022
We investigated the prognostic impact of the neutrophil‐to‐lymphocyte ratio (NLR) in patients with head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors (ICIs).
Y. Takenaka, Ryohei Oya, N. Takemoto, H. Inohara +3 more
semanticscholar +1 more source

Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinoma

Head and Neck, 2019
Inflammation and immune evasion are associated with carcinogenesis. Systemic Inflammation Response Index (SIRI) has been proposed as a pretreatment peripheral blood biomarker.
C. Valero +6 more
semanticscholar +1 more source

Platelet count and platelet‐lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Meta‐analysis

Head and Neck, 2018
Thrombocytosis is associated with the prognosis of various types of cancer. The purpose of this study was to quantify the prognostic impact of platelet count and platelet‐lymphocyte ratio (PLR) in head and neck squamous cell carcinoma (HNSCC).
Y. Takenaka +7 more
semanticscholar +1 more source

Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual

Ca-A Cancer Journal for Clinicians, 2017
William M Lydiatt, Snehal G Patel, Brian O'Sullivan +2 more
exaly

Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data